Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe
June 23, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...
Clinical Trials Market to Surpass US$ 177.7 Billion Valuation by 2033 Owing to the Development of Precision Medicines and Therapeutic Approaches | Future Market Insights, Inc.
February 07, 2023 08:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The global Clinical Trials Market is anticipated to augment at a flourishing CAGR of 4.41% over the forecast period from 2023 to 2033. The global...
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
December 14, 2022 10:47 ET
|
Clinical Ink
Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
November 30, 2022 15:01 ET
|
POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
Patient Registry Software Market is Expected to Reach USD 2.50 Bn by 2031: Allied Market Research
October 10, 2022 12:30 ET
|
Allied Market Research
Portland, OR, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the Global Patient Registry Software Market generated $993.3 million in 2021, and is...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
September 20, 2022 21:31 ET
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
November 18, 2021 17:00 ET
|
RadioMedix Inc.
Houston, TX, Nov. 18, 2021 (GLOBE NEWSWIRE) -- RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II...
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
October 13, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
December 03, 2019 08:00 ET
|
Dermavant Sciences, Inc.
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 ...
Eko Launches ‘Eko Home,' a Cardiac Remote Monitoring Application Enabling Powerful Drug-Data Combinations to Enhance Clinical Studies and Pharmaceutical Trials
July 25, 2019 13:00 ET
|
Eko
San Francisco, July 25, 2019 (GLOBE NEWSWIRE) -- Eko, a Silicon Valley-based digital health company applying machine learning in the fight against heart disease, today announced Eko Home, a...